TIDMEDX

RNS Number : 4134O

EDX Medical Group PLC

02 October 2023

Posting of Notice of GM and Annual Report

EDX Medical Group plc -- EDX

2 October 2023

EDX Medical Group plc ("EDX Medical" or the "Company"), which develops innovative digital diagnostic products and services supporting personalised treatment solutions for cancer, heart disease, neurology and infectious diseases, announces that a general meeting ("GM") will be held at 10 Stratton Street, London W1J 8LG on 25 October 2023 at 2:00 p.m.

The annual report and financial statements for the year ended 31 March 2023, Notice of GM and Form of Proxy will be posted today, 2 October 2023, to eligible shareholders. Electronic copies will be shortly available on the Company's website at: https://edxmedical.co.uk/documents/.

Contacts:

 
 EDX Medical plc 
 Dr Mike Hudson (Chief Executive       +44 (0)7812 345 301 
  Officer)                              mike@edxmedical.co.uk 
 
 Oberon Capital 
 Nick Lovering (Corporate Adviser) 
  Adam Pollock (Corporate Broking) 
  Mike Seabrook (Corporate Broking)    +44 (0)20 3179 5300 
 
 Media House International 
 Ramsay Smith (Executive Director)     +44 (0)7788 414856 
                                        ramsay@mediahouse.co.uk 
  Gary McQueen (Associate Director)     + 44 (0)7834 694609 
                                        gary@mediahouse.co.uk

Notes for Editors:

About EDX Medical Group plc ( www.edxmedical.co.uk )

EDX Medical Group plc develops innovative digital diagnostic products and services, enabling cost effective and timely delivery of personalised treatment for cancer, heart disease, and infectious diseases. The company is listed on the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost-effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.

EDX Medical operates a molecular biology and diagnostics laboratory in Cambridge, UK, and 100%-owned subsidiary companies, Hutano Diagnostics Limited in Oxford, UK, and Torax Biosciences Ltd ( www.toraxbiosciences.co.uk ) in Ireland.

EDX Medical provides testing and genomic sequencing services, undertakes quality assurance, conducts research & development (R&D) and has established expertise in the design, development, validation and sourcing of diagnostic testing solutions to ISO 13485. Key laboratory tests performed by the Company have been accredited to ISO 15189 by the United Kingdom Accreditation Service (UKAS).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXUPGPAUUPWGWP

(END) Dow Jones Newswires

October 02, 2023 10:15 ET (14:15 GMT)

EDX Medical (AQSE:EDX)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025 Click aqui para mais gráficos EDX Medical.
EDX Medical (AQSE:EDX)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025 Click aqui para mais gráficos EDX Medical.